^
Association details:
| Biomarker: | DNMT3A mutation |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | RVU120 (CDK19 inhibitor, CDK8 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PRECLINICAL AND CLINICAL SIGNS OF RVU120 EFFICACY, A SPECIFIC CDK8/19 INHIBITOR IN DNMT3A MUTATION POSITIVE AML AND HR-MDS
Published date:
05/12/2022
Excerpt:
...13 patients have been enrolled into CLI120-001 trial, including 2 patients with DNMT3A mutations….Second DNMT3A mutation patient with HR-MDS, escalated from 50 to 75 mg dose from cycle 7, continues treatment at the cycle 24 with SD and erythroid hematological improvement...Preliminary evidence of clinical response to RVU120 has been also shown in R/R AML and HR-MDS patients positive for DNMT3A mutations.
